<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05062200</url>
  </required_header>
  <id_info>
    <org_study_id>CR109097</org_study_id>
    <secondary_id>77242113PSO1002</secondary_id>
    <nct_id>NCT05062200</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-77242113 in Healthy Japanese Participants and a Single Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-77242113 in Healthy Chinese Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Pharmaceutical K.K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Pharmaceutical K.K.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK)&#xD;
      of JNJ-77242113 after single ascending oral dose administration in Japanese healthy&#xD;
      participants and after single oral dose administration in Chinese healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 25, 2021</start_date>
  <completion_date type="Anticipated">December 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parts 1 and 2: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 1 and 2: Plasma Concentration of JNJ-77242113</measure>
    <time_frame>Predose up to 48 hours postdose (Up to Day 3)</time_frame>
    <description>Plasma samples will be analyzed to determine concentrations of JNJ-77242113 using a validated, specific and sensitive method.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1: JNJ-77242113 or Placebo (Single Ascending Dose [SAD])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese participants will receive single oral dose 1 of JNJ-77242113 or matching placebo on Day 1 in Cohort 1 of Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: JNJ-77242113 or Placebo (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese participants will receive single oral dose 2 of JNJ-77242113 or matching placebo on Day 1 in Cohort 2 of Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: JNJ-77242113 or Placebo (Single Dose [SD])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chinese participants will receive single oral dose 2 of JNJ-77242113 or matching placebo on Day 1 in Cohort 3 of Part 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-77242113</intervention_name>
    <description>JNJ-77242113 will be administered as an oral tablet.</description>
    <arm_group_label>Cohort 1: JNJ-77242113 or Placebo (Single Ascending Dose [SAD])</arm_group_label>
    <arm_group_label>Cohort 2: JNJ-77242113 or Placebo (SAD)</arm_group_label>
    <arm_group_label>Cohort 3: JNJ-77242113 or Placebo (Single Dose [SD])</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo will be administered as an oral tablet.</description>
    <arm_group_label>Cohort 1: JNJ-77242113 or Placebo (Single Ascending Dose [SAD])</arm_group_label>
    <arm_group_label>Cohort 2: JNJ-77242113 or Placebo (SAD)</arm_group_label>
    <arm_group_label>Cohort 3: JNJ-77242113 or Placebo (Single Dose [SD])</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For Part 1: Japanese male or female of non-childbearing potential, who have parents&#xD;
             and maternal and paternal grandparents who are of Japanese ethnicity&#xD;
&#xD;
          -  For Part 2: Chinese male or female of non-childbearing potential, who have parents and&#xD;
             maternal and paternal grandparents who are of Chinese ethnicity&#xD;
&#xD;
          -  Healthy on the basis of physical examination, medical history, vital signs, and&#xD;
             12-lead electrocardiogram (ECG) performed at screening. If there are abnormalities,&#xD;
             they must be consistent with the underlying illness in the study population. This&#xD;
             determination must be recorded in the participant's source documents and initialed by&#xD;
             the investigator&#xD;
&#xD;
          -  Body weight not less than 50 kilograms (kg) and body mass index within the range 18&#xD;
             and 30 kilograms per meter square (kg/m^2) (inclusive)&#xD;
&#xD;
          -  Blood pressure (after the participant is supine for 5 minutes) between 90 and 140&#xD;
             millimeters of mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg&#xD;
             diastolic. If blood pressure is out of range, up to 2 repeated assessments are&#xD;
             permitted&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of malignancy before screening (exceptions are squamous and basal cell&#xD;
             carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is&#xD;
             considered cured with minimal risk of recurrence)&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients&#xD;
&#xD;
          -  Use of a live vaccine within 30 days prior to screening or anticipated need for a live&#xD;
             vaccine during the study or for 30 days following the dose of study drug&#xD;
&#xD;
          -  Received an experimental drug (including investigational vaccines) or used an&#xD;
             experimental medical device within 1 month or within a period less than 10 times the&#xD;
             drug's half-life, whichever is longer, before the dose of the study intervention is&#xD;
             scheduled&#xD;
&#xD;
          -  Test positive for human immunodeficiency virus (HIV)-1 and 2 antigen/antibodies, test&#xD;
             positive for hepatitis C antibodies, test positive for syphilis, or test positive for&#xD;
             hepatitis B virus (HBV) infection at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Pharmaceutical K.K., Japan Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Pharmaceutical K.K.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Souseikai Hakata Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR109097</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

